N

Nykode Therapeutics ASA
OSE:NYKD

Watchlist Manager
Nykode Therapeutics ASA
OSE:NYKD
Watchlist
Price: 2.134 NOK -6.65% Market Closed
Market Cap: 696.8m NOK
Have any thoughts about
Nykode Therapeutics ASA?
Write Note

Intrinsic Value

NYKD's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one NYKD stock under the Base Case scenario is 0.188 NOK. Compared to the current market price of 2.134 NOK, Nykode Therapeutics ASA is Overvalued by 91%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

NYKD Intrinsic Value
0.188 NOK
Overvaluation 91%
Intrinsic Value
Price
N
Base Case Scenario

Valuation Backtest
Nykode Therapeutics ASA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for NYKD cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about NYKD?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Biotechnology Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Nykode Therapeutics ASA

Provide an overview of the primary business activities
of Nykode Therapeutics ASA.

What unique competitive advantages
does Nykode Therapeutics ASA hold over its rivals?

What risks and challenges
does Nykode Therapeutics ASA face in the near future?

Summarize the latest earnings call
of Nykode Therapeutics ASA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Nykode Therapeutics ASA.

Provide P/S
for Nykode Therapeutics ASA.

Provide P/E
for Nykode Therapeutics ASA.

Provide P/OCF
for Nykode Therapeutics ASA.

Provide P/FCFE
for Nykode Therapeutics ASA.

Provide P/B
for Nykode Therapeutics ASA.

Provide EV/S
for Nykode Therapeutics ASA.

Provide EV/GP
for Nykode Therapeutics ASA.

Provide EV/EBITDA
for Nykode Therapeutics ASA.

Provide EV/EBIT
for Nykode Therapeutics ASA.

Provide EV/OCF
for Nykode Therapeutics ASA.

Provide EV/FCFF
for Nykode Therapeutics ASA.

Provide EV/IC
for Nykode Therapeutics ASA.

Show me price targets
for Nykode Therapeutics ASA made by professional analysts.

What are the Revenue projections
for Nykode Therapeutics ASA?

How accurate were the past Revenue estimates
for Nykode Therapeutics ASA?

What are the Net Income projections
for Nykode Therapeutics ASA?

How accurate were the past Net Income estimates
for Nykode Therapeutics ASA?

What are the EPS projections
for Nykode Therapeutics ASA?

How accurate were the past EPS estimates
for Nykode Therapeutics ASA?

What are the EBIT projections
for Nykode Therapeutics ASA?

How accurate were the past EBIT estimates
for Nykode Therapeutics ASA?

Compare the revenue forecasts
for Nykode Therapeutics ASA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Nykode Therapeutics ASA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Nykode Therapeutics ASA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Nykode Therapeutics ASA compared to its peers.

Compare the P/E ratios
of Nykode Therapeutics ASA against its peers.

Discuss the investment returns and shareholder value creation
comparing Nykode Therapeutics ASA with its peers.

Analyze the financial leverage
of Nykode Therapeutics ASA compared to its main competitors.

Show all profitability ratios
for Nykode Therapeutics ASA.

Provide ROE
for Nykode Therapeutics ASA.

Provide ROA
for Nykode Therapeutics ASA.

Provide ROIC
for Nykode Therapeutics ASA.

Provide ROCE
for Nykode Therapeutics ASA.

Provide Gross Margin
for Nykode Therapeutics ASA.

Provide Operating Margin
for Nykode Therapeutics ASA.

Provide Net Margin
for Nykode Therapeutics ASA.

Provide FCF Margin
for Nykode Therapeutics ASA.

Show all solvency ratios
for Nykode Therapeutics ASA.

Provide D/E Ratio
for Nykode Therapeutics ASA.

Provide D/A Ratio
for Nykode Therapeutics ASA.

Provide Interest Coverage Ratio
for Nykode Therapeutics ASA.

Provide Altman Z-Score Ratio
for Nykode Therapeutics ASA.

Provide Quick Ratio
for Nykode Therapeutics ASA.

Provide Current Ratio
for Nykode Therapeutics ASA.

Provide Cash Ratio
for Nykode Therapeutics ASA.

What is the historical Revenue growth
over the last 5 years for Nykode Therapeutics ASA?

What is the historical Net Income growth
over the last 5 years for Nykode Therapeutics ASA?

What is the current Free Cash Flow
of Nykode Therapeutics ASA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Nykode Therapeutics ASA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Nykode Therapeutics ASA

Current Assets 140m
Cash & Short-Term Investments 136.5m
Receivables 3.5m
Non-Current Assets 39.9m
PP&E 9.3m
Intangibles 72k
Other Non-Current Assets 30.5m
Current Liabilities 15.1m
Accounts Payable 3.4m
Other Current Liabilities 11.7m
Non-Current Liabilities 12.7m
Long-Term Debt 3.4m
Other Non-Current Liabilities 9.3m
Efficiency

Earnings Waterfall
Nykode Therapeutics ASA

Revenue
6.1m USD
Operating Expenses
-65m USD
Operating Income
-58.9m USD
Other Expenses
20.9m USD
Net Income
-37.9m USD

Free Cash Flow Analysis
Nykode Therapeutics ASA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

Nykode Therapeutics announced a significant strategic repositioning focusing their VB10.16 program on locally advanced cervical cancer and metastatic head and neck cancer. This decision, driven by feasibility and market potential, led to the discontinuation of the C-04 trial. Despite a net loss of $7.4 million in Q2, Nykode maintained a robust cash position of $136.5 million. They also highlighted promising data in their autoimmune platform and mRNA vaccine technologies, and reaffirmed commitments to their Genentech and Regeneron partnerships.

What is Earnings Call?
Fundamental Scores

NYKD Profitability Score
Profitability Due Diligence

Nykode Therapeutics ASA's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Positive 3-Year Average ROE
Negative 1-Year Revenue Growth
Declining ROE
25/100
Profitability
Score

Nykode Therapeutics ASA's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

NYKD Solvency Score
Solvency Due Diligence

Nykode Therapeutics ASA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Nykode Therapeutics ASA's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NYKD Price Targets Summary
Nykode Therapeutics ASA

Wall Street analysts forecast NYKD stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NYKD is 23.052 NOK with a low forecast of 10.1 NOK and a high forecast of 52.5 NOK.

Lowest
Price Target
10.1 NOK
373% Upside
Average
Price Target
23.052 NOK
980% Upside
Highest
Price Target
52.5 NOK
2 360% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for NYKD?

Click here to dive deeper.

Dividends

Nykode Therapeutics ASA
does not pay dividends
Shareholder Yield

Current shareholder yield for NYKD is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Nykode Therapeutics ASA

Country

Norway

Industry

Biotechnology

Market Cap

696.9m NOK

Dividend Yield

0%

Description

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.

Contact

OSLO
Oslo
Oslo Science Park, Gaustadalleen 21
+4722958193
nykode.com

IPO

2020-01-27

Employees

135

Officers

Chief Executive Officer
Mr. Michael Thyring Engsig
Chief Financial Officer
Mr. Harald Gurvin
Chief Technology Officer
Mr. Ulrich Blaschke
Chief Scientific Officer & Business Development
Dr. Agnete B. Fredriksen Ph.D.
Chief Legal Officer
Ms. Louise Stubbe
Chief Research & Development Officer
Dr. Klaus Edvardsen M.D., Ph.D.

See Also

Discover More
What is the Intrinsic Value of one NYKD stock?

The intrinsic value of one NYKD stock under the Base Case scenario is 0.188 NOK.

Is NYKD stock undervalued or overvalued?

Compared to the current market price of 2.134 NOK, Nykode Therapeutics ASA is Overvalued by 91%.

Back to Top